Menarini takes on sponsorship of myeloid leukemia drug in USA
Menarini Ricerche, a part of Italian family-controlled drugmaker Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) in the USA has been transferred from Poland’s Selvita (WSW: SLV) to Menarini Ricerche on June 30, 2018.
Menarini Ricerche has assumed full responsibility for clinical development activities after a period of very productive collaboration with Selvita.
In March 2017, Menarini, through its subsidiary Berlin-Chemie Menarini, entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor then in Phase I/II trials in acute myeloid leukemia (AML) patients, with Selvita, under a deal worth around $105 million to the Polish biotech firm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze